Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

pursuant to which the Company was paid a $200,000 cash purchase price in exchange for 54.5% of future quarterly royalty payments on net sales of MAVYRET/MAVIRET, after June 30, 2023, through June 30, 2032, subject to a cap on aggregate payments equal to 1.42 times the purchase price.

There is a typo in there as ENTA got $200 million ($200,000,000) not $200,000.